fludarabine + cyclophosphamide

• Healthcare
• Pharma & Biotech
• Switzerland

Novartis: Arzerra significantly improves median progression-free survival when added to fludarabine + cyclophosphamide after initial treatment stopped working in patients with relapsed chronic lymphocytic leukemia

Arzerra significantly improved PFS when added to fludarabine + cyclophosphamide (median 28.9 mos vs 18.8 mos) after initial treatment stopped…